What is RDNT's current stock price?

RDNT (RadNet, Inc.) is currently trading at $54.40 with a market cap of $4.28B.

What sector is RadNet, Inc. in?

RadNet, Inc. (RDNT) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.

Is RDNT a good stock to buy?

Analysts have a Buy consensus on RDNT with a price target of $86.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

RDNT RadNet, Inc.

Healthcare

$54.40-0.07%ClosedMarket Cap: $4.28B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.88

P/S

1.99

EV/EBITDA

17.83

DCF Value

$-36.60

FCF Yield

-3.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

9.4%

Operating Margin

3.8%

Net Margin

-0.7%

ROE

-1.4%

ROA

-0.4%

ROIC

1.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$575.6M	$-33.5M	$—
Q4 null	$547.7M	$-597.0K	$—
FY null	$2.04B	$-18.7M	$—
Q3 null	$522.9M	$5.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$86.00

Target (Median)

$91.00

Target Range

$65.00 - $92.00

2 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

BarclaysOverweight

2026-05-20

B. Riley SecuritiesBuy

2025-12-01

BarclaysOverweight

2025-11-13

Truist SecuritiesBuy

2025-11-12

BarclaysOverweight

2025-09-03

Trading Activity

Insider Trades

View All

Berger Howard Gdirector, officer: President, CEO

SellWed May 06

Sorensen Alma Gregorydirector, officer: Chief Strategy Officer

SellMon Mar 23

Sorensen Alma Gregorydirector, officer: Chief Strategy Officer

SellMon Mar 23

Sorensen Alma Gregorydirector, officer: Chief Strategy Officer

SellMon Mar 23

Sorensen Alma Gregorydirector, officer: Chief Strategy Officer

SellMon Mar 23

Company Info

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Country

Exchange

—

Beta

1.43

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

Peers

CHE

SHC